Assetmark, Inc Aerie Pharmaceuticals Inc Transaction History

Assetmark, Inc

  • $36.4 Billion
  • Q4 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2015

Sep 15, 2017
BUY
N/A
7
7 $0

Others Institutions Holding AERI

# of Institutions
3
Shares Held
2.4M
Call Options Held
0
Put Options Held
0
View Full List

About AERIE PHARMACEUTICALS INC

AERI Quotes by TradingView
  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email